Background: Peritoneal dialysis (PD) is an ideal model for testing remote monitoring (RM). In this study, we evaluated the RM application longitudinally in stable patients undergoing automated PD (APD). Methods: This was an observational study, comparing outcomes in patients with (current patients) and without (historical data) exposure of RM. We analyzed cost-effectiveness of RM-APD measuring the number of night alarms, number of hospital visits, direct and indirect costs. Results: Changes in APD prescription were almost double in the case group (RM) compared to the control group (p = 0.0005). The need for in-person visits and nocturnal alarms was significantly less in RM-APD than in traditional APD (p = 0.01 and p = 0.002, respectively). The distance traveled by patients in the case of RM-APD was reduced by 1,134 km with a time saving of 1,554 min for patients. The overall cost reduction for the PD center in terms of time/nurse and time/physician was 2,647 and 3,673 min, respectively. All these advantages were obtained in the presence of an improved technique survival with a significant reduction of dropouts. All patients found that it is easy to use the RM system and were satisfied with the high level of interaction with the care team and with the possibility of timely resolving technical problems. Conclusion: These data confirm the long-term benefits of RM applied to APD. RM-APD is cost-effective; it allows early detection and resolution of problems, improved treatment compliance, reduction of patient’s access to hospital center for technical and clinical complications with consequent savings, and improved patient’s quality of life.

Keywords:
Remote monitoring, Automated peritoneal dialysis, Telemedicine, Inperson visit, Night alarms, Long-term peritoneal dialysis
1.
Dombros N, Dratwa M, Feriani M, Gokal R, Heimburger O, Krediet R, Plum J, Rodrigues A, Selgas R, Struijk D, Verger C: European best practice guidelines for peritoneal dialysis. 7 Adequacy of peritoneal dialysis. Nephrol Dial Transplant 2005; 20(suppl 9):ix24–ix27.
2.
Rosner MH, Ronco C: Remote monitoring for continuous peritoneal dialysis. Contrib Nephrol 2012; 178: 68–73.
3.
Martino F, Adibelli Z, Mason G, Nayak A, Ariyanon W, Rettore E, Crepaldi C, Rodighiero M, Ronco C: Home visit program improves technique survival in peritoneal dialysis. Blood Purif 2014; 37: 286–290.
4.
Harrington DM, Myers L, Eisenman K, Bhise V, Nayak KS, Rosner MH: The use of a tablet computer platform to optimize the care of patients receiving peritoneal dialysis: a pilot study. Blood Purif 2014; 37: 311–315.
5.
Francois K, Ronco C, Bargman JM: Peritoneal dialysis for chronic congestive heart failure. Blood Purif 2015; 40: 45–52.
6.
Lu R, Mucino-Bermejo MJ, Ribeiro LC, Tonini E, Estremadoyro C, Samoni S, Sharma A, Zaragoza Galvan Jde J, Crepaldi C, Brendolan A, Ni Z, Rosner MH, Ronco C: Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review. Cardiorenal Med 2015; 5: 145–156.
7.
He T, Liu X, Li Y, Wu Q, Liu M, Yuan H: Remote home management for chronic kidney disease: a systematic review. J Telemed Telecare 2017; 23: 3–13.
8.
Karopadi AN, Mason G, Rettore E, Ronco C: Cost of peritoneal dialysis and haemodialysis across the world. Nephrol Dial Transplant 2013; 28: 2553–2569.
9.
Rojahn K, Laplante S, Sloand J, Main C, Ibrahim A, Wild J, Sturt N, Areteou T, Johnson KI: Remote monitoring of chronic diseases: a landscape assessment of policies in four European countries. PLoS One 2016; 11:e0155738.
10.
Cafazzo JA, Leonard K, Easty AC, Rossos PG, Chan CT: Patient perceptions of remote monitoring for nocturnal home hemodialysis. Hemodial Int 2010; 14: 471–477.
11.
Nayak A, Antony S, Nayak KS: Remote monitoring of peritoneal dialysis in special locations. Contrib Nephrol 2012; 178: 79–82.
12.
Milan Manani S, Crepaldi C, Giuliani A, Virzi GM, Garzotto F, Riello C, de Cal M, Rosner MH, Ronco C: Remote monitoring of automated peritoneal dialysis improves personalization of dialytic prescription and Patient’s independence. Blood Purif 2018; 46: 111–117.
13.
Gallar P, Vigil A, Rodriguez I, Ortega O, Gutierrez M, Hurtado J, Oliet A, Ortiz M, Mon C, Herrero JC, Lentisco C: Two-year experience with telemedicine in the follow-up of patients in home peritoneal dialysis. J Telemed Telecare 2007; 13: 288–292.
14.
Magnus M, Sikka N, Cherian T, Lew SQ: Satisfaction and improvements in peritoneal dialysis outcomes associated with telehealth. Appl Clin Inform 2017; 8: 214–225.
15.
Ronco C, Fecondini L: The Vicenza wearable artificial kidney for peritoneal dialysis (ViWAK PD). Blood Purif 2007; 25: 383–388.
16.
Wallace EL, Rosner MH, Alscher MD, Schmitt CP, Jain A, Tentori F, Firanek C, Rheuban KS, Florez-Arango J, Jha V, Foo M, de Blok K, Marshall MR, Sanabria M, Kudelka T, Sloand JA: Remote patient management for home dialysis patients. Kidney Int Rep 2017; 2: 1009–1017.
17.
Makhija D, Alscher MD, Becker S, D’Alonzo S, Mehrotra R, Wong L, McLeod K, Danek J, Gellens M, Kudelka T, Sloand JA, Laplante S: Remote monitoring of automated peritoneal dialysis patients: assessing clinical and economic value. Telemed J E Health 2018; 24: 315–323.
18.
Ding H, Jayasena R, Maiorana A, Dowling A, Chen SH, Karunanithi M, Layland J, Edwards I: Innovative Telemonitoring Enhanced Care Programme for Chronic Heart Failure (ITEC-CHF) to improve guideline compliance and collaborative care: protocol of a multicentre randomised controlled trial. BMJ Open 2017; 7:e017550.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.